Drug Trial Radar · NCT07826455
A Study to Evaluate Tegoprazan as a Diagnostic Tool for GERD
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Jul 31, 2028
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- HK inno.N CorporationIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the diagnostic value of tegoprazan for GERD. Patients experiencing typical GERD symptoms, such as heartburn and acid regurgitation, will take either tegoprazan or a placebo once daily for 1 week. Investigators will compare the short-term symptom improvement between the two groups to determine if an early response to tegoprazan can help diagnose GERD.
Conditions
- GERD (Gastroesophageal Reflux Disease)
Interventions
Tegoprazan 50 mgDrug
Tegoprazan 50 mg tablet will be orally administered once daily for 7 days.
PlaceboDrug
Placebo tablet will be orally administered once daily for 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnostic accuracy (Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value) of GERD based on total symptom scoreTime frame: Day 7
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.